Table 2 Prophylactic vaccines targeting hr-HPV
From: Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use
Name | Valents | Targets | Adjuvants | Expression system | Current progress | Eligible age and sex | References |
|---|---|---|---|---|---|---|---|
Gardasil | 4 | HPV-16/18/6/11 | Amorphous aluminum hydroxy phosphate sulfate | Recombinant Saccharomyces cerevisiae, Yeast | Approved in 2006 | Females aged 9–26 | |
Cervarix | 2 | HPV-16/18 | 3-0-Desacyl-4′-monophosphoryl lipid A, Aluminum hydroxide salt | Trichoplusia ni insect cells, Baculovirus | Approved in 2009 | Females aged 9–25 | |
Gardasil-9 | 9 | HPV-16/18/31/33/45/52/58/6/11 | Amorphous aluminum hydroxy phosphate sulfate | Recombinant Saccharomyces cerevisiae, Yeast | Approved in 2014 | Females aged 9–45 | |
Cecolin | 2 | HPV-16/18 | Aluminum hydroxide | Escherichia coli | Approved in 2019 | Females aged 9–45 | |
Cecolin-9 | 9 | HPV-16/18/31/33/45/52/58/6/11 | Aluminum hydroxide | Escherichia coli | phase II clinical trial completed | Females aged 9–45 | |
Cervavac | 4 | HPV-16/18/6/11 | Aluminum based | Hansenula polymorpha | Approved in 2022 | Females and males aged 9–26 | |
Walvax recombinant HPV vaccines | 2 | HPV-16/18 | Aluminum phosphate | Pichia pastoris, Yeast | Approved in 2022 | Females aged 9–30 |
